A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)

This study tests the combination of tucatinib (a targeted HER2 therapy) and T-DM1 (an antibody-drug that delivers chemotherapy directly to HER2-positive tumor cells) in patients with HER2-positive cancers that have spread to the brain. HER2-positive means the tumor has an excess of a protein called HER2, which can drive cancer growth. **You may be eligible if...** - You are 18 or older - You have confirmed HER2-positive metastatic solid tumor cancer - Your cancer has spread to the brain (either untreated brain metastases not requiring immediate surgery/radiation, or previously treated brain metastases) - You are in good enough health to tolerate the treatment **You may NOT be eligible if...** - Your brain metastases are rapidly growing and require immediate treatment - You have severe liver, heart, or other organ problems - You have had certain prior treatments that would make this combination unsafe - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.